Interv Akut Kardiol. 2008;7(6):215-218

Platelet polymorphisms and feasibility of monitoring of antiplatelets therapy results

Jan Kvasnička, Jaroslava Hájková, Petra Bobčíková

Trombotické centrum Všeobecné fakultní nemocnice, Praha

The aim of study was to assess the frequencies of platelet polymorphisms which are connected with „aspirin resistance“ or/and variability of clopidogrel response in Czech population.

The anonymous testing of 1,450 blood donors DNA by PCR using Light Cycler 480 (ROCHE) were used in finding of GP IIIa (HPA-1; rs5918), P2Y12 (H1/H2 haplotype; rs2046934) and COX-1 (-842A/G; rs10306114) polymorphisms frequencies.

Results: The frequencies of GP IIIa (HPA1) were: 27.40 % heterozygotes, 3.66 % homozygotes and 68.94 % wild type homozygotes, frequencies of P2Y12 (H1/H2 haplotype) were 25.92 % heterozygotes, 2.63 % homozygotes and 71.46 % wild type homozygotes and frequencies of COX-1 (-842A/G) were 12.00 % heterozygotes, 0.41 % homozygotes and 87.59 % wild type homozygotes in tested group of healthy persons.

In conclusion, the frequencies are in accordance with estimated 10–40 % variability of antiplatelets drug response.

The paper also reviews the impact of laboratory assays for routine monitoring of antiplatelet therapy.

Keywords: resistance to therapy, platelets polymorphisms, frequencies, platelet function, laboratory tests

Published: December 20, 2008  Show citation